CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that management is scheduled to present at the
following upcoming healthcare conferences in New York, NY.
— Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4th
at 3:20 p.m. Eastern Time.
— Barclays Capital Small & Mid-Cap Healthcare Forum on Thursday, November
6th at 2:30 p.m. Eastern Time.
— Rodman & Renshaw Annual Global Healthcare Conference on Tuesday,
November 11th 5:20 p.m. EST.
A live audio webcast of the presentations will be available by accessing
DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.”
If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing
innovative drugs for pain and other chronic diseases, with late-stage
development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM) and
TRANSDUR(TM)-Sufentanil. DURECT’s proprietary oral, transdermal and
injectable depot delivery technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved convenience,
compliance, efficacy and safety for small molecule and biologic drugs. For
more information, please visit http://www.www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM) and ELADUR(TM) are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the US Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation
CONTACT: Matthew J. Hogan, Chief Financial Officer of DURECT
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, firstname.lastname@example.org
Web site: http://www.www.durect.com